Tyrosine kinase inhibitor and application thereof
AssigneeLaNova Medicines Limited Company
InventorsFang Sun, Youni Zhan
Life of this patent
Estimating the term…
Abstract
The invention discloses a compound with the following formula (I), wherein, K is selected from: cycloalkyl and halo alkyl or N—R6. The invention also discloses a tyrosine kinase inhibitor containing the above compound and the use of the compound in preparing drugs for treating cancers. The tyrosine kinase inhibitor of the invention can inhibit the bioactivity of multiple signal conduction kinases such as C-MET, VEGF, KDR, etc., can effectively inhibit cell proliferation and has favorable therapeutic effects on various diseases such as cancer. In particular, the present invention has significant therapeutic effects especially on lung cancer, gastric cancer, ovarian cancer, malignant glioma, etc., and has a very broad application prospect.
Claims10
A compound of formula of (I)
- or a pharmaceutically acceptable salt thereof, wherein,
- K is selected from the group consisting of
- and N—R6;
- b and d are 1, 2, 3 or 4;
- E and G are one of hydrogen, halogen, hydroxy, alkoxy, ketone, sulfydryl and alkyl sulfydryl, but E and G cannot be hydrogen at the same time;
- R6 is one of hydrogen, halo alkyl, halogenated cycloalkyl, alkyl and cycloalkyl;
- R1, R2, R3, R4 and R5 are one or several of hydrogen, halogen, halo alkyl, halogenated cycloalkyl, alkyl, cycloalkyl, hydroxy, alkoxy, cycloalkoxy, alkenyl and alkynyl, respectively;
- X is one of C—R, C—(CN) and N, and R is one of hydrogen, halogen, halo alkyl, halogenated cycloalkyl, alkyl, cycloalkyl, hydroxy, alkoxy, cycloalkoxy, alkenyl and alkynyl;
- Y is one of O, S and N—R6 or is null, and M is O or null;
- a and c represent 0, 1, 2 or 3, respectively;
- and e is 1 or 2.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.